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Abstract
Objective: Pulmonary hypertension (PH) and elevated pulmonary vascular resistance (PVR) lead to poor outcome after heart transplantation
due to postoperative failure of the non-conditioned right ventricle. The role of continuous flow left ventricular assist device (LVAD) support in
the reduction of elevated PVR was evaluated in a series of clinical implants. Methods: Among 17 patients with terminal heart failure receiving a
MicroMed DeBakey LVAD as bridge to transplant, there were six patients with pulmonary hypertension (mean systolic PAP 47 mmHg) and high
PVR (398 dyne s/cm5), previously not considered suitable for heart transplantation, who underwent serial right heart catheters during their
LVAD support period. Results: In these patients mean systolic pulmonary pressure dropped to 29 mmHg and PVR decreased to a mean
167 dyne s/cm5 under LVAD support. Clinical improvement was significant in all patients. Four patients were successfully transplanted without
major postoperative difficulties (mean duration 130 days support) and all are doing well to date. Post-transplant-PVR remained in the normal
range in all transplanted patients. Conclusions: Elevated PVR and severe PH were both previously considered as contraindication for heart
transplantation. A period of LVAD pumping leads to a progressive decrease of PVR and normalization of pulmonary pressures, making these
patients amenable for heart transplantation. LVAD as bridge to heart transplantation is safe and highly beneficial for terminal heart failure
patients with severe PH.
q 2004 Elsevier B.V. All rights reserved.
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Terminal heart failure brings with it a high morbidity
and mortality rate, with therapeutic options remaining
limited for this ever-increasing population. Orthotopic
heart transplantation is the gold standard for these
patients [1]. It renders reasonable quality of life while
significantly increasing life expectancy [1,2]. Due to the
shortage of donor organs and medical contraindications to
heart transplantation, mechanical circulatory support
(MCS) such as left ventricular assist devices (LVAD) have
shown to be very beneficial as a bridge to transplantation
[3,4]. Furthermore as an alternative to heart transplan-
tation in terminal heart failure, the REMATCH trial has
established LVADs as such [5–7]. Disease progression brings
backward failure, which in turn alters the pulmonary
circulation ultimately leading to decreased right1010-7940/$ - see front matter q 2004 Elsevier B.V. All rights reserved.
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leading to changes of the pulmonary vasculature, which
at first seems to be reversible, but over time becomes
irreversible. On a capillary level, increased vascular
remodeling, in situ thrombosis and vasoconstriction are
all perpetuating mechanisms, leading to fixed pulmonary
hypertension (PH) [8]. Fixed PH and high PVR are both
tributaries of advancing heart failure and lead to poor
outcome after heart transplantation due to the post-
operative failure of the non-conditioned right ventricle [9]
increasing early morbidity and mortality. However after
heart transplantation, 80% of survivors will normalize their
PVR at 1 year [10–12], highlighting the fact that even with
fixed PH, reversal of pulmonary disease is achieved with
through normalized blood flow, as seen in patients under
LVAD support.
The role of LVAD support, especially with the new
continuous flow devices, as provided by new generation
LVADs, was evaluated in a series of clinical implants. We
studied the role of LVAD support as bridge to heart
transplantation, but more specifically we identified a subset
of patients with pulmonary hypertension (PH) and high
pulmonary vascular resistance (PVR).European Journal of Cardio-thoracic Surgery 27 (2005) 222–225www.elsevier.com/locate/ejcts
Table 1
Inclusion criteria
Left atrial or pulmonary capillary wedge pressure O188 mmHg
Mean arterial pressure !90 mmHg
Cardiac index !2.0 l/min per m2
LVEF !25%
Incomplete response to intravenous therapy
IABP
High risk of sudden cardiac death, and
Accepted by multidisciplinary institutional transplantation committee
Table 3
Preoperative patients hemodynamics
Patient HR (bpm) Mean AOP
(mmHg)
Mean PA
(mmHg)
PVR
(dyn s cmK5)
1 100 85 28 467
2 80 69 37 501
3 90 70 48 327
4 95 62 25 305
5 88 60 26 340
6 84 67 40 450
HR, heart rate; AOP, aortic pressure; PA, pulmonary artery pressure; PVR,
pulmonary vasculature resistance.
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2.1. Study population and protocol
Over a period of 45 months from October 1999 until June
2003 a total of 17 patients were enrolled in a multicenter
phase III trial evaluating the DeBakey LVAD (MicroMed Inc,
Houston, TX) as a bridge to heart transplantation. All 17
patients (mean age 42 years (18–64)), received a DeBakey
LVAD as a bridge to transplantation. Inclusion criteria for this
study are resumed in Table 1. Over the course of LVAD
support the following parameters were followed in all
patients: plasma BNP, hepatic and renal function, hemolysis,
and pump-parameters such as revolutions per minute, flow
and power consumption.
A subset of six patients with elevated PVR and pulmonary
hypertension (mean PA pressure O25 mmHg) where ident-
ified by preoperative pulmonary artery catheterization.
Within this group, four patients were seen to have fixed
pulmonary hypertension as defined by the lack of significant
decrease of pulmonary artery pressures following vasodila-
tor testing. Table 2 shows patient’s demographics, and
Table 3 the hemodynamics in this patient subset prior to
LVAD implantation.
All patients were operated on electively under cardio
pulmonary bypass with cannulation of femoral artery and
vein and on the beating heart, as previously reported [4].
This subset of patients was then prospectively followed
during the bridge to transplant support period especially in
regard to PA pressures. The patients underwent measure-
ment of their PA pressures by serial postoperative right heart
catheters. During the entire LVAD support period, these
patients were removed from the heart transplantation list.
Once clinical status improved, right heart catheters showedTable 2
Preoperative patient demographics
Patient 1 2 3 4 5 6
Age (years) 48 41 37 52 64 61
Sex F M M M M M
Height (cm) 172 176 186 182 185 170
Weight (kg) 67 72 92 92 64 68
HR (bpm) 100 80 90 95 88 84
AOP (mmHg) 105/75 100/54 90/60 85/50 80/50 85/65
NYHA III IV III III III III
Etiology RCMP CAD CAD CAD VALV DIL
Redo-surgery No No Yesa No Yesb No
AOP, aortic pressure; NYHA, New York Heart Association; RCMP, restrictive
cardiomyopathy; CAD, coronary artery disease; VALV, valvular heart disease;
M, male; F, female.
a Previous coronary artery bypass grafting.
b Previous aortic valve replacement.a significant decrease in PA pressures and PVR, and a positive
metabolic status was achieved, the decision to put these
patients on the list with a ‘super-urgent’ status was taken.
This research was conducted with approval by the
institutional review board of the University Hospital of
Zurich. All patients signed an informed consent prior to
enrollment.
A precise description of the DeBakey LVAD was done
previously by Noon et al. [13]. Details of this series, such as
outcome, anticoagulation and clinical follow-up have
recently been published by our team [4].
2.2. Statistical analysis
Hemodynamic and clinical data are reported as meanG
range. Paired variables were analysed by paired Student’s
t-test and unpaired variables were compared using the
Wilcoxon non-parametric test. A P value less than 0.05 was
deemed significant.3. Results
3.1. LVAD implantation and support period
LVAD implantation was successful in all six patients.
Operative mortality for this subset was 0 vs. 21.5% in the
entire bridge to transplant group (P!0.05). Duration of
surgery was 156 (110–200) min. The mean ICU stay was 16
days (5–58). Of the six patients only one patient required use
of inhaled nitric oxide (NO) for early postoperative RV failure
after LVAD implantation, during a period of 12 h. The same
patient required prolonged ventilation and subsequent
tracheostomy due to iatrogenic lesion with a TEE probe to
the soft palate. The patient recovered and was weaned from
the respirator and discharged from the ICU after 58 days.
Serial right heart catheters were done on these six study
patients. After a period of 6 weeks, the mean PVR decreased
from 398 (501–305) to 167 (74–216) dyne s cmK5 (Fig. 1),
systolic pulmonary artery pressure from a mean of 47 (29–67)
to 29 (12–49) mmHg (Fig. 2), P!0.05 in all.
Patients increased their exercise tolerance with maxi-
mum achieved power increasing from a mean of 35 to 71 W
(P!0.05). Plasma BNP dosages were also done in this patient
population, values dropped significantly during support
period from 950 to 162 ng/l (P!0.05). Functional status
measured by NYHA classification decreased from 4 to 1.5
(P!0.05). One patient suffered from a 7-h episode of
Fig. 1. PVR during LVAD support (nZ6).
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lowing electro conversion he remained in sinus rhythm for
over 3 weeks (see case report) [14]. Two patients died while
on support in this subgroup at days 81 (unknown cause) and
76 (thrombo-embolic event, see case report [14]).
3.2. Heart transplantation procedure and follow-up
Four patients underwent successful heart transplantation
after a mean duration of 130 (25–355) days. Only one patient
required the use of inhaled nitric oxide in the early post-
operative period after transplantation. Operative mortality
was 0% and all patients were discharged. Mortality after a
mean of 24-month follow-up remains 0%. Follow-up right
heart catheters have shown all patients to have normal PA
pressures and PVR.4. Conclusions
4.1. LVAD as bridge to transplant
The DeBakey LVAD was the first new generation of LVAD,
with continuous flow to offer a new alternative for the
treatment of terminal heart failure [15]. As bridge to
transplant, LVAD’s now seem to be established. The benefit
of increased end-organ perfusion with very small, fully
implantable devices seems substantial in ensuring good
outcome of LVAD support and heart transplantation,
especially with the acute donor organ shortage present
around the world. This is the first report of a homogenous
series of patients with high PVR and pHTN receiving the same
type of LVAD. Martin et al. [16] just recently reported their
experience in similar patients undergoing LVAD implantation
with intent to treat pulmonary hypertension inFig. 2. Pulmonary systolic pressures during LVAD support (nZ6).transplantation candidates. In our series we obtained similar
results with patients normalizing their PVR within 6 weeks
and significantly bettering their clinical status. Furthermore,
we experienced very few adverse events, and no device
related events occurred in our series.
4.2. LVAD and pulmonary circulation
Some authors advocate use of right ventricular support in
patients with high PVR and pHTN. It seems however that with
the advent of these new micro-axial continuous flow pumps,
the mechanisms leading of right heart failure may be altered.
The left and right ventricles are closely interdependent, with
the use of pulsatile LVADs the unloading of the ventricle,
especially the left, is not continuous during the cardiac
cycle. These new continuous flow pumps unload the ventricle
during the entire cardiac cycle, leading to a geometric
restoration of ventricular geometry (left and right). Further-
more the lateral shift of the septum which occurs when the
left ventricle is not sufficiently unloaded, is decreased in
these scenarios. In addition to a continuous negative
pressure at the inflow cannula of the LVAD in the left
ventricle, both these effects lead to an increased transpul-
monary flow. Increased LV compliance during systole,
decreased RV dilatation and less tricuspid insufficiency, all
may contribute to the clinical improvement in these patients
[17]. The role of possible associated resynchronization
therapy, i.e. biventricular pacing and continuous flow LVAD
support seems like a very interesting combination in this
patient population and warrants further investigation.
The early postoperative period has been identified by
many authors as a critical period in patients with high PVR
and pHTN leading to a low threshold for additional right
ventricular assist device placement [18]. However there has
been a lack of evidence in regard to PVR being a risk factor
for postoperative right ventricular failure [19]. It is our
belief that both pharmacological management (inotropic
support), volume loading and fine tuning of pump par-
ameters (rpm and flow adjustments, but also cardiac pacing)
can avoid the necessity of right ventricular support. We use a
low rpm/flow setting in the early phases of LVAD implan-
tation to allow the aortic valve to open, but also to prevent
septal shift in hypovolemic states leading to decreased right
ventricular function and hemodynamically significant
arrhythmias. All these measures are intended to ensure
efficacious synchrony between the actively unloaded left
ventricle and the passively assisted right ventricle. Once the
early postoperative phase is overcome the flow can gradually
be increased to match the clinical needs of these patients.
4.3. Outcome after heart transplantation
Elevated PVR and PH, medically unresponsive or fixed PH
were previously considered contraindications for heart
transplantation [20]. This study suggests that LVAD support
allows continuous reduction of post capillary load inducing
normalization of PVR in patients otherwise not considered as
transplantation candidates. As reports have previously
shown, normalization of high PVR and pulmonary hyperten-
sion does occur after heart transplantation [10,12]. LVAD as
bridge to transplant is safe and beneficial for terminal heart
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patients with pulmonary hypertension to convert from
ineligible to eligible in regard to heart transplantation status
[21]. In our opinion, emergency heart transplantation is
obsolete with the advent of LVAD therapy, especially in
regard to the high mortality associated with emergency
procedures [22]. Offering patients with terminal heart
failure the option of mechanical circulatory support is a
big therapeutic opening, which will save lives.
On the other hand, elevated PVR and fixed PH, notions
incompatible with successful heart transplantation in the
past, need to be revisited. Furthermore, this hemodynamic
preconditioning, with LVAD and/or new pharmacologic
agents prior to cardiac surgery seem to lead to excellent
functionality of the pulmonary vasculature and come with
increased postoperative survival.References
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